Product Information
OPVEE 2.7 MG NASAL SPRAY is a brand product labeled by Indivior Inc., priced at $46.7881 per EA under NDC 12496000302. Its NADAC has been published 59 times since Aug 20, 2025.
FDA first approved this application on May 22, 2023.
Strength
2.7 mg/100uL
Manufacturer
Indivior Inc.NDC
12496000302
Classification
Brand
Dosage Form
SPRAY
Route
NASAL
Effective Date
9/23/2026
Active Ingredients
NALMEFENE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA217470FDA Approved
5/22/2023
On Market Since
10/2/2023
Pharmacological Classes
Price Statistics
The NADAC for OPVEE 2.7 MG NASAL SPRAY has been published 59 times since Aug 20, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $46.7881 per EA |
|---|---|
| All-time high | $46.8392 (Apr 15, 2026) |
| All-time low | $46.7321 (Oct 22, 2025) |
| 52-week high | $46.8392 |
| 52-week low | $46.7321 |
| Median price | $46.7881 |
| Average price | $46.7854 |
| Largest weekly change | -0.2% (Oct 22, 2025) |
| Weeks tracked | 59 |
| Tracking since | Aug 20, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the nalmefene hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Indivior Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
nalmefene hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Opioid Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OPVEE 2.7 MG NASAL SPRAY?
The current National Average Drug Acquisition Cost (NADAC) for OPVEE 2.7 MG NASAL SPRAY, manufactured by Indivior Inc., is $46.7881 per EA (NDC 12496000302), effective Sep 30, 2026.
How has the price of OPVEE 2.7 MG NASAL SPRAY changed over time?
Over the history we have for it, the NADAC for OPVEE 2.7 MG NASAL SPRAY has held within roughly two percent of its current level. It has been tracked across 59 weekly CMS publications since Aug 20, 2025.
What are the highest and lowest recorded NADAC prices for OPVEE 2.7 MG NASAL SPRAY?
Since Aug 20, 2025, the NADAC for OPVEE 2.7 MG NASAL SPRAY has ranged from a low of $46.7321 (Oct 22, 2025) to a high of $46.8392 (Apr 15, 2026), with a median of $46.7881 per EA.
Are there cheaper alternatives to OPVEE 2.7 MG NASAL SPRAY?
No other NADAC-published product currently shares the active ingredient and strength of OPVEE 2.7 MG NASAL SPRAY in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures OPVEE 2.7 MG NASAL SPRAY?
OPVEE 2.7 MG NASAL SPRAY (NDC 12496000302) is labeled by Indivior Inc., and CMS classifies it as a brand product.